In a report released on April 22, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...